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Abstract
Background: Cancer relapses may be useful to predict the risk of death. To take into account relapse information,
the Landmark approach is popular. As an alternative, we propose the joint frailty model for a recurrent event and a
terminal event to derive dynamic predictions of the risk of death.
Methods: The proposed prediction settings can account for relapse history or not. In this work, predictions developed
on a French hospital series of patients with breast cancer are externally validated on UK and Netherlands registry data.
The performances in terms of prediction error and calibration are compared to those from a Landmark Cox model.
Results: The error of prediction was reduced when relapse information was taken into account. The prediction was
well-calibrated, although it was developed and validated on very different populations. Joint modelling and Landmark
approaches had similar performances.
Conclusions: When predicting the risk of death, accounting for relapses led to better prediction performance. Joint
modelling appeared to be suitable for such prediction. Performance was similar to the landmark Cox model,
while directly quantifying the correlation between relapses and death.
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Background
Individual predictions are increasingly sought after to
help guide treatment decisions and patient care. Accu-
rate predictions are especially important in the context of
personalised medicine, where the ultimate goal is to give
personalised targeted treatment to every patient. To do so,
it is important to evaluate patient prognosis, accounting
for their individual characteristics. In recent years, prog-
nosis research in cancer has focused mainly on the pres-
ence of biomarkers that can be targeted by treatments.
Less focus has been given to the impact of relapses that
patients may experience, such as loco-regional relapses or
distant metastases in cancer patients, which may explain a
large part of the risk of death, despite adequatemethods of
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analysis currently available. The impact of these relapses
on the risk of death may vary according to the type of can-
cer. Relapses can be considered as a surrogate for patient
frailty or for disease aggressiveness. It is therefore of inter-
est to investigate how these events can be used to predict
patient survival.
Relapses are recurrent events, evolving during patient
follow-up. Thus it is of interest to study the impact
of recurrences on death. However, relapses and death
are non-independent events, sometimes called semi-
competing risks, and relapses cannot be included in a
survival model as a standard time-dependent covariate
to study the risk of death [1]. The Landmark approach
[2,3] resolves the problem by updating the population of
interest. At each chosen prediction time, the model is
estimated again on patients still alive. Thus, relapse his-
tory, observed before the prediction time, can be resumed
as a baseline covariate, such as the number of previous
relapses. This method offers the advantage of a simple and
robust model. However, to do some dynamic predictions
using several prediction times, several models have to be
© 2015 Mauguen et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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run on sub-populations of alive patients. Moreover, sum-
marising the relapse process in a single variable may result
in a loss of information.
Alternatively, joint modelling can be used to study
recurrent events [4,5]. The hazard of the recurrent event
and the hazard of the terminal event (death) are jointly
modelled. Such models allow us to fully consider the cor-
relation between the two processes using a shared random
effect (frailty). Dynamic predictions can then be derived,
accounting for all previous events. Once the parameters
are estimated, predictions can be updated without run-
ning the model again. A recent work investigated the
impact of relapses on the risk of death in breast can-
cer using a joint frailty model [6]. The proposed method
was shown to be an adequate framework for prediction,
and the model seemed to give a satisfying performance
on the sample used to develop the model (development
sample). However, the high number of parameters to be
estimated may be a concern in prediction context, espe-
cially for generalisability purpose. It is therefore essen-
tial to validate the proposed prediction on independent
data [7-9].
Here, our main goal is to validate a method of predic-
tions from a joint model for recurrent events and death
as accurate predictions. We present the results of the
external validation of the previously developed prediction
based on relapses in addition to well-known prognostic
factors [6]. In order to assess whether the high num-
ber of parameters is a concern, we compare this new
prediction performances with those of a Landmark Cox
model. As in the development step, we apply the pro-
posed prediction on breast cancer cases, here from two
population-based registries, in West Midlands (England)
and the Netherlands.
Section “Methods” of this paper explains the predic-
tion probabilities within the framework of a Landmark
Cox model and a joint frailty model, as well as the tools
to validate them. The validation of the prediction on the
WestMidlands and Netherlands registry datasets is devel-
oped in section “Results”. Finally, sections “Discussion”
and “Conclusion” contain concluding remarks.
Methods
We are interested in the prediction of the risk of death
between a prediction time s and a prediction horizon s+w
considering all the information available at time s. The
information includes some baseline covariates, but also
history of recurrent events (loco-regional relapse or dis-
tant metastasis) until time s. In this context, the predicted
risk of death can be updated after each new recurrence.
Prediction of death in the joint modelling framework
The joint frailty model for a recurrent event and a ter-
minal event is defined as follows [5]: for subject i (i =
1, . . . ,N), let Xij be the jth recurrent time (j = 1, . . . , ni)
measured from the study origin (calendar time), Di be
the death time and Ci be the independent censoring time.
Note that the censoring time can happen to be a recur-
rence time. TRij = min(Xij,Ci,Di) corresponds to each
follow-up time and δRij is a binary indicator for recurrent
events which is 0 if the observation is censored or if the
subject died, and 1 if Xij is observed
(
δRij = I
[
TRij = Xij
]
where I[ .] denotes indicator function). Similarly, we note
TDi as the last follow-up time for subject i, which is either
a time of censoring or a time of death
(
TDi = min(Ci,Di)
)
and δDi = I
[
TDi = Di
]
. We actually observe the sequence(
TRij , δRij ,TDi , δDi
)
. Finally, we denote by ZRij and ZDi the vec-
tors of covariates associated with the hazard of recurrent
events and death, respectively. However, a patient is con-
sidered at risk of a jth recurrence only after the (j − 1)st
recurrence. The joint model is then written as:{
λRij(t|ui) = uiλR0 (t) exp
(
β ′1ZRij
)
= uiλRij(t)
λDi (t|ui) = uαi λD0 (t) exp
(
β ′2ZDi
) = uαi λDi (t) (1)
where λR0 (.) is the baseline hazard of a recurrent event,
irrespective of event rank, and λD0 (.) the baseline hazard
of death. The effects of explanatory variables β1 and β2
are assumed to be different for the hazard of recurrent
events and the risk of death. The two processes are linked
by the patient-specific frailty effect ui. The frailty terms
are independent and identically distributed following a
gamma distribution with variance θ and, without loss of
generality, a mean equal to 1. That is:
ui ∼ Gamma
( 1
θ
; 1
θ
)
and g(ui) = u
1/θ−1 exp(−u/θ)
θ1/θ(1/θ)
(2)
The baseline hazard functions (λR0 (.) for recurrent
events and λD0 (.) for death) are approximated using cubic
splines, but alternative flexible functions such as frac-
tional polynomials could be used. Splines are piecewise
polynomials that are constrained to smoothly joint to fit
curves. We used λR0 (.) =
∑m
i=1 ηRi Mi(.) and λD0 (.) =∑m
i=1 ηDi Mi(.) where Mi(.) is the common basis splines,
and ηR and ηD the two vectors of splines coefficients.
The parameters of the model ξ = (ηR, ηD,β1,β2,α, θ)
are estimated using penalized maximum likelihood esti-
mators. For more details on the inference method, please
see [5]. To estimate this model, all the available informa-
tion is used, from the origin to the end of follow-up of all
patients.
Using the joint modelling framework, we are interested
in two prediction settings previously defined [6]. The first
prediction of the risk of death PRec is calculated based
on all relapses information. In this setting, the J relapses
occurring before the prediction time s are considered (J ≤
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ni). We consider the patient history HJi (s) = {NRi (s) =
J ,Xi1 < . . . < XiJ ≤ s}, with Xi0 = 0 and Xi(J+1) > s, to
define the conditional probability of death PRec as follows:
PRec(s, s + w; ξ)
=P
(
Di ≤ s + w|Di > s,HJi (s),ZRs,ij ,ZDs,i, ξ
)
=
∫∞
0
[
SDi
(
s|ZDs,i,ui, ξ
)−SDi (s + w|ZDs,i,ui, ξ)] (ui)J SRi(J+1)(s|ZRs,ij ,ui, ξ)g(ui)dui∫∞
0 SDi
(
s|ZDs,i,ui , ξ
)
(ui)J SRi(J+1)
(
s|ZRs,ij ,ui, ξ
)
g(ui)dui
(3)
whereZRs,ij andZDs,i are the values of the covariates at time s,
and g(ui) is the density of the gamma distribution defined
in equation (2).
The second setting PIgn also uses the joint modelling
framework. However, while recurrences information is
used in model estimation, the information about previous
recurrences is not considered in the prediction, and it can
be missing. It is defined by:
PIgn(s, s + w; ξ)
= P (Di ≤ s + w|Di > s,ZDs,i, ξ)
=
∫∞
0
[
SDi
(
s|ZDs,i,ui, ξ
)− SDi (s + w|ZDs,i,ui, ξ)] g(ui)dui∫∞
0 SDi
(
s|ZDs,i,ui, ξ
)
g(ui)dui
(4)
Both settings are dynamic in the sense that the pre-
diction can be updated by changing the prediction time
s, thus the quantity of available information, and/or the
prediction window w. The first setting considers the indi-
vidual relapse history, whereas the second ignores it.
Prediction of death using a Landmark Cox model
The Landmark approach involves fixing a prediction time
s and fitting the model on the sub-group of patients still at
risk of death at this time, that is, patients alive and not lost
to follow-up [2]. Thus, the number of relapses occurring
before time s can be treated as a baseline covariate, and the
recurrences occurring after s are ignored. This covariate
can be updated when another Landmark time s is con-
sidered, and a new model is fitted. With this approach, a
robust model can be used, requiring few parameters, and
the time-dependent effects are easily dealt with. However,
only a sub-group of alive patients is included to fit the
model, which may result in a loss of information in the
parameter estimation.
We have Di the death time and Ci the independent cen-
soring time. Let λDs,i
(
.|ZDs,i
)
denote the hazard function of
death conditional on being alive at the Landmark time s,
λDs,0(.) be the conditional baseline hazard function, ZDs,i be
the covariate vector at time s and βs be their effect esti-
mated at time s. The Landmark Cox model is then written
as follows:
λDs,i
(
t|ZDs,i
) = λDs,0(t) exp (β ′sZDs,i) , for t ≥ s (5)
This model is estimated with the information available
at the Landmark time s. The prognostic factors of inter-
est ZDs,i may include information about previous recurrent
events, for example, their frequency and timing. The base-
line hazard of death λDs,0(.) is estimated using splines with
parameters ηDs . The parameters of the model ξLMs =
(ηDs ,βs) are estimated using penalized maximum likeli-
hood estimators as in [5]. The corresponding prediction
of the risk of death is written as:
PLM
(
s, s + w; ξLMs
)
= P (Di ≤ s + w|Di > s,ZDs,i, ξLMs )
= S
D
i
(
s|ZDs,i, ξLMs
)− SDi (s + w|ZDs,i, ξLMs )
SDi
(
s|ZDs,i, ξLMs
) (6)
where SDi (.|ZDs,i, ξLMs ) is the survival function conditional
on being alive at time s associated to the hazard of death.
External validation of the prediction
In order to make predictions using the three proposed
settings PLM, PRec and PIgn on new patients, the model
parameters are estimated on the development sample.
Based on these estimators, predictions for new patients
are obtained by replacing the patient level information,
ZDs,i in equation (6) or J , ZRs,ij and ZDs,i in equations (3) and
(4), with actual information on the new patient.
The quality of fit of the two models can be compared
on the development data using an approximate likelihood
cross-validation criterion as in [10].
Prediction error
To estimate if the predictions are accurate, error of pre-
diction curves are used, based on the Brier score. The
Brier score aims to measure how far the prediction is from
the actual outcome of the patients. We used a weighted
estimator of the Brier score to account for right censor-
ing using the Inverse Probability of Censoring Weights
(IPCW) [11].
LetNs be the number of patients alive and uncensored at
prediction time s, that is, patients for whom the prediction
can be made. Given TDi the possibly right-censored sur-
vival time, δDi the corresponding event indicator (δDi = 1
if the observed time is a death time, 0 otherwise). We
denote ĜN (.) the Kaplan-Meier estimate of the censoring
distribution on the sample. Using the generic term Pˆ(s, s+
w; ξˆ ) which can be one of the three prediction probabil-
ity settings previously described, the error of prediction is
defined by:
Errs,w = 1Ns
Ns∑
i=1
[
I
(
TDi > s + w
)− (1 − Pˆ (s, s + w; ξˆ))]2
× hˆi
(
s + w, GˆN (.)
)
with hˆi(s+w, GˆN (.)) being a weight that accounts for right
censoring:
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hˆi
(
s + w, GˆN (.)
)
= I
(
TDi ≤ s + w
)
δDi
GˆN
(
TDi
)
/GˆN (s)
+ I
(
TDi > s + w
)
GˆN (s + w) /GˆN (s)
The performance of the models is compared using a
measure of explained residual variation defined as follows
[12]:
R2 = 1 − Errs,wErrs,w;KM
where Errs,w is the error of one of the predictions (PLM,
PRec or PIgn) described as above and Errs,w;KM is the error
of prediction using the Kaplan-Meier estimate at s + w
in the entire set of patients. It can be interpreted as how
much the prediction error is decreased using the model-
based prediction as compared to an average prediction
estimated by Kaplan-Meier.
The proposed error of prediction is calculated in two
different ways: either s is fixed and w varies, or s varies
while w is fixed.
Calibration plot
Another indicator of the accuracy of the prediction tool
proposed is the calibration [13]. A well-calibrated pre-
diction means that, among 100 patients with a predicted
event risk of p%, p of them will actually experience the
event. This can be computed only for a binary endpoint,
meaning that we must choose a time of prediction. We set
it at s + w = 10 years.
The calibration is illustrated using a calibration plot.
The predicted risks of death are grouped according to
the deciles of their distribution. For each decile, the
observed proportion of an event is plotted against the
mean predicted value, along with the 95% confidence
interval for the observed proportion. For a well-calibrated
prediction, all points should fall very close to the first
bisector.
On the calibration plot the histogram of the predicted
values is also represented, showing how they are dis-
tributed between 0 and 1.
Software
Joint model and predictions were computed using the R
functions frailtyPenal and prediction from the R package
frailtypack [14]. The Brier score were computed using the
R package pec [15]. The calibration plots were drawn using
R software (code available as Additional file 1).
Ethical approval and availability of supporting data
For the French hospital series, ethical approval from
the national ethics committee (Commission Nationale de
l’Informatique et des Libertés) was obtained for this study,
which allowed the use of data recorded in this clinical and
pathological database. In this comprehensive cancer cen-
ter, each patient was informed that medical data can be
use in observational research. The procedure follows the
French law for medical research. We hold statutory and
ethical approvals to analyse the data from West Midlands
Cancer Intelligence Unit and Comprehensive Cancer Cen-
tre The Netherlands registry data.
All data used are confidential. Researchers may access
the data by sending a formal request to the appropriate
institution (Institut Bergonié for the French series, West
Midlands Cancer Intelligence Unit for the UK registry
data and Comprehensive Cancer Centre The Netherlands
for the Dutch registry data).
Results
Population comparison
The first validation sample consisted of all breast can-
cer cases diagnosed in West Midlands, England, in 1996
and followed until 2012. The second validation sample
consisted of cases from the Netherlands Cancer Registry,
South Netherlands region excluded, diagnosed between
2003 and 2006 and followed until the end of 2012. Because
the vital status of the patients is ascertained in both
registries through a passive approach, no lost to follow-
up is assumed. The development cohort consisted of
1067 patients operated in a comprehensive cancer cen-
tre between 1989 and 1993, and with a median follow-up
of 14 years. Thus, the two validation populations dif-
fer from the development population in terms of coun-
try and selection of population (general population in
West Midlands and Netherlands; hospital-based patients
in France) and inclusion period (1996 and 2003-2006 vs.
1989-1993).
In the two validation samples, a high rate of missing
data was observed. Out of the 3168 cases recorded in the
year 1996 in West Midlands, 1196 (38%) had non-missing
values for all of the five studied prognostic factors. In
the Dutch sample, information about peritumoural vas-
cular invasion was not recorded. Of the 41,676 recorded
patients, 31,075 (75%) had non-missing values for the
four remaining factors. In our validation sample, we
included only patients with complete information in the
two datasets. This decision is discussed in the last part of
the paper.
Table 1 compares the repartition of the prognosis fac-
tors in the three samples, as well as the number of
relapses per patient, and the overall survival. Patients
in both validation samples had more severe disease, i.e.,
more peritumoural vascular involvement (38.5% in West
Midlands vs. 26.7%), a tumour size greater than 20 mm
(46.8% in West Midlands and 39.8% in Netherlands vs.
22.7%) and grade III disease (37.1% in West Midlands
and 33.8% in Netherlands vs. 24.6%), despite a similar
age. As a result, overall survival in both West Midlands
and Netherlands was lower than in the development
cohort.
The number of relapses per patient also varied. There
were up to four relapses recorded in the West Midlands
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Table 1 Description of the three samples used to develop (n=1067) and validate themodel (n=3168 and n=31,075)
French cohort West Midlands Netherlands
(1989-1993) (1996) (2003-2006)
Variable N=1067 % N=1196 % N=31075 %
Age
Age ≤40 82 7.7 73 6.1 2126 6.8
Age [40-55] 391 36.6 456 38.1 10681 34.4
Age >55 594 55.7 667 55.8 18268 58.8
Peritumoural vascular involvement 285 26.7 460 38.5 - -
Tumour size > 20 mm 242 22.7 560 46.8 12365 39.8
Nodal involvement 451 42.3 496 41.5 12588 40.5
Grade
Grade I 316 29.6 226 18.9 6565 21.1
Grade II 488 45.7 526 44.0 13993 45.0
Grade III 263 24.6 444 37.1 10517 33.8
Number of recurrent events
None 705 895 27231
1 301 240 3834
2 57 49 10
3 4 10 0
4 0 2 0
5-year survival 89.1 (87.3-91.0) 76.6 (74.2-79.0) 85.5 (85.1-85.9)
10-year survival 77.1 (74.6-79.7) 63.1 (60.5-65.9) -
15-year survival 65.4 (62.2-68.2) 51.6 (48.8-54.5) -
sample compared with a maximum of two in the Dutch
sample and three in the development cohort. In the
West Midlands registry, relapses were not collected but
retrieved from the treatment information with an algo-
rithm that uses the treatment type and time interval
between successive treatments [16]. In the Dutch sam-
ple, relapse data was obtained directly from patient files;
both clinically and pathologically confirmed relapses were
recorded. The recording was limited to relapses occur-
ring during the first five years after diagnosis and, in
some regions, to the first relapse of each type (local
relapse, regional relapse or distant metastasis). In the
French cohort, relapses (loco-regional recurrence or dis-
tant metastasis) were recorded following a clinical exam-
ination. That resulted in 75% of the patients without
registered relapse in theWest Midlands, 88% in the Dutch
sample, and 66% in the French cohort.
Validation of the prediction
Models
The results of the joint frailty model and the Landmark
Coxmodel (thereafter called Landmark model), estimated
on the French data, are shown in Table 2. The prognos-
tic factors kept for prediction were those associated with
the risk of recurrent events or with the risk of death in
the joint model. The joint model estimation (first and
second columns) showed that the risk of recurrent event
was higher in younger women (age ≤ 40), in women
with peritumoural vascular involvement, in women with
larger tumour (tumour size >20 mm), in women with
nodal involvement, and in women with grade other than
I. The risk of death was decreased for women between
40 and 55-year old, and increased in women with peritu-
moural vascular involvement, with large tumour size, with
nodal involvement, and with grade other than I. The vari-
ance of the random effects θ differed significantly from
zero, meaning that there exists an heterogeneity between
patients regarding their risk of recurrence and death, and
that this heterogeneity could not be totally explained by
the measured prognostic factors. The α > 0 showed that
the patients at higher risk of relapses were also at higher
risk of death. Results of the Landmark model are shown in
the last column. The main difference is that only the effect
of covariates on the risk of death are estimated, and the
estimations were adjusted parametrically on the number
of relapses. As a consequence, the Landmark model pro-
vided lower estimated effects than with the joint model.
After adjustment on the number of relapses, only the pres-
ence of a nodal involvement was significantly associated
with a higher risk of death, and both age lower than or
Mauguen et al. BMCMedical ResearchMethodology  (2015) 15:27 Page 6 of 12
Table 2 Joint and Landmark Coxmodels estimations on the French cohort (n=1067 patients, 427 recurrent events)
Joint model Cox landmark
For recurrent events For death For death
Variable HR (95% CI) HR (95% CI) HR (95% CI)
Age
[ 40 − 55] vs. > 55 1.17 (0.91-1.51) 0.31 (0.16-0.60) 0.56 (0.41-0.76)
≤ 40 vs. > 55 2.41 (1.73-3.37) 1.57 (0.73-3.38) 0.54 (0.31-0.92)
Peritumoural vascular involvement 1.61 (1.26-2.06) 4.74 (2.54-8.85) 1.04 (0.76-1.43)
Tumour size (> 20 mm vs. ≤ 20 mm) 1.95 (1.52-2.50) 6.21 (2.99-12.86) 1.20 (0.88-1.65)
Nodal involvement 1.84 (1.44-2.36) 4.89 (2.47-9.67) 1.95 (1.45-2.60)
Grade
II vs. I 2.18 (1.57-3.01) 7.48 (2.71-20.66) 1.07 (0.75-1.52)
III vs. I 3.09 (2.16-4.41) 44.33 (15.61-125.93) 1.25 (0.83-1.88)
Recurrences before t = 5 years
One previous recurrence 7.18 (5.25-9.83)
Two previous recurrences 6.94 (3.05-15.83)
θ = var(ui) 1.07 (se=0.06)
α 4.45 (se=0.33)
LCV 1.19 0.93
HR: Hazard ratio; CI: Confidence interval; LCV: Likelihood cross-validation criterion; Cox Landmark at time t = 5 years.
equal to 40, and age between 40 and 55 years were asso-
ciated with a lower risk of death. The Landmark model
also showed an important effect of the number of previ-
ous relapses. The likelihood cross-validation criterion was
lower for the Landmark model (0.93 versus 1.19), suggest-
ing that this model fitted the data better than the joint
model. However, a better fit does not necessarily result in
better prediction [17].
Prediction error
Overall, all of the studied prediction settings gave better
results than the Kaplan-Meier, with a higher R2 for both
predictions accounting for relapses (Figure 1). In theWest
Midlands, when the time of prediction s is at five years
(Figure 1B), R2 was as high as 80% for early predictions
and regularly decreased with increasing prediction hori-
zon (30% at 10 years). The gain in the prediction error
diminished with the prediction horizon, being around
50% at seven years and ending around 17% at 15 years,
showing that the information from themodel had a higher
impact on short-term prediction. R2 was still around 20%
at a horizon of 15 years, but very similar for the three
settings. R2 was low, under 20%, for shorter prediction
time (s = 2 years; see Figure 1A). This illustrates the
fact that the information gathered up to two years was
not enough to obtain good prediction, especially consider-
ing relapses. In the Dutch sample (Figures 1C and D), the
limited follow-up prevented us from studying prediction
times longer than three years. The results were very sim-
ilar to those in the West Midlands sample at s = 2 years,
but the difference between the three settings was larger.
Results were better for the prediction from the Landmark
model, and worse for the prediction ignoring the relapse
information.
When holding the prediction window at w = 2 or w = 5
years, results were similar (Figures 2A and B, respectively).
The setting ignoring relapses always gave lower perfor-
mance, while the performances of the two other settings
were very similar. The more information that was col-
lected and used, the more accurate the prediction was, as
shown by the curves increasing with time of prediction t,
for both window times. As expected, the entire curve was
higher (i.e., lower error of prediction) when the prediction
was made for a shorter window (two years as compared to
five years).
Calibration
All three settings gave good calibration, with points
around the first bisector (Figure 3). Interestingly, both pre-
diction approaches accounting for relapses identified a
group of patients with high risk of death in both samples.
For these high-risk patients, the mean predicted risk was
somewhat lower than the observed risk (40% in the West
Midlands vs. 50% in the Netherlands using PRec). The his-
tograms show that predicted values were lower overall for
the Landmark approach (rarely exceeding 20%) whereas
both predictions from the joint model gave higher risks.
This may explain why the observed probability of death
seemed underestimated with the Landmark approach in
the West Midlands.
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Figure 1 Error of prediction on validation samples for the three predictions. A. On the West Midlands sample, at the prediction time t = 2
years and a prediction horizon from 2.5 to 15 years. B. On the West Midlands sample, at the prediction time t = 5 years and a prediction horizon
from 5.5 to 15 years. C. On the Dutch sample, at the prediction time t = 2 years and a prediction horizon from 2.5 to 7 years. D. On the Dutch
sample, at the prediction time t = 3 years and a prediction horizon from 2.5 to 7 years.
Additional validation by subgroups
The validation samples differed in many aspects from
the development sample. Thus, even if good results were
observed for the proposed prediction both in terms of
prediction error and of calibration, it is crucial to check
the accuracy of the prediction on a more similar sam-
ple. For these subgroups analyses, the model is still
developed on the whole French cohort; only the pre-
diction is made on a subgroup of the English sample.
Here we selected a subsample of operated patients, as
it was the main selection criterion in the development
sample.
Similar results were observed with the 602 oper-
ated patients from the West Midlands (Figure 4). Large
confidence intervals were observed due to the reduced
number of subjects included in this analysis (n=417
patients alive at five years). Calibration was not better than
as observed on the entire West Midlands data.
A second subgroup analysis was performed compar-
ing the performance of the proposed predictions between
subjects who relapsed at least once before the predic-
tion time of five years and those who did not (Figure 5).
As expected, in the subgroup of patients without relapse,
the results were very similar to those in the entire sam-
ple. However, no high-risk subject groups were identified,
as observed in the main analysis. In the subsample with
relapses, the prediction ignoring the relapses underesti-
mated the observed probabilities of events (all the points
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Figure 2 Error of prediction on theWest Midlands sample when the prediction time t is increasing from 0 to 10 and the window of
prediction is set at A. 2 years and B. 5 years.
are above the line) and had a very low R2, negative after
7.5 years.
Discussion
To account for the recurrent events and their association
with the risk of death, we used a joint frailty model for
recurrent events and a terminal event. This framework
appears suitable to derive such predictions. The obtained
prediction gave a similar error of prediction to a Cox
model in a Landmark approach. The two approaches have
modelling assumptions. Both are proportional hazards
models. In both models, we estimated the baseline haz-
ards with a semi-parametric approach using splines. It was
compared to a non-parametric estimation of the baseline
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Figure 3 Calibration plot for the three predictions of death between 5 and 10 years in theWest Midlands sample (left panel) and between
2 and 7 years in the Dutch sample (right panel).
hazard, and both approaches gave very similar results
(data not shown). The landmarking approach allows the
use of a simple and robust model, such as the Cox model.
Moreover the covariates effects are re-estimated at each
prediction times. However, only the alive patients are kept
to estimate the model. By contrast, the joint model use
all the sample patients and parameters are estimated once
to do predictions. However, assumptions are made on
the frailty structure and distribution. We can note that in
the hypothesis of no association between the relapse and
death processes (i.e., parameter α = 0), the prediction of
death in the joint model simplifies to an expression similar
to equation (6), independent of the risk of relapses. Wait-
ing for a more careful comparison of the two approaches,
the choice between the joint and the Landmark approach
should thus be mainly guided by the willingness (i) to fully
describe both processes (recurrent event and death) and
their correlation (joint model); or (ii) to focus only on the
death (Landmark approach). A Landmark approach using
a non-parametric prediction was also recently proposed
to predict a long-term outcome accounting for a short-
term event [18].
Initially, the proposed prediction incorporated informa-
tion about the human epidermal growth factor receptor
2 (HER-2) status and hormonal receptor status. However,
considering the non-availability of this information at the
general population level at the time of this data collection,
we have re-estimated the model and prediction without
this information. On the initial development sample, we
compared the prediction error of the two joint models,
with and without this biological information. The pre-
diction error was very similar for both models (data not
shown).
One perspective of such prediction can be its use in
clinical trials context. Indeed, the validation of surrogate
markers in several cancers, such as the progression-free
survival as a surrogate for the overall survival, raises the
question about how to use the progression-free survival
information in practice. One of the options is to use pro-
gressions to predict the risk of death in the two arms to
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Figure 4 Results of the prediction on the operated patients fromWest Midlands. A. Relative prediction error at the prediction time t = 5 years
and a prediction horizon from 5.5 to 15 years. B,C,D. Calibration plots for the three predictions.
be able to conclude earlier on the treatment effect [19]. In
that perspective, the prediction that we validated maybe
useful.
In the context of the jointmodelling framework, the pre-
diction of recurrent events can also be derived. Moreover,
our analyses indicate that each prognostic factor con-
sidered separately adds very little prediction information
once the baseline hazard and recurrent event processes
are adequately modelled (data not shown). The covari-
ates may be of greater interest when predicting the risk
of a recurrent event. Considering relapse type differently
(loco-regional relapse and metastasis) can also be of inter-
est as they reflect various severity levels of the disease [20].
Finally, these predictions could be extended in the context
of competing risks or excess mortality, where it would be
possible to focus on predicting only the risk of death from
cancer.
Finally, prognostic research literature is lacking when
it comes to the consequences of missing data on the
validation process, i.e., after the development phase. No
prediction can be done if one of the covariates is missing.
However, the impact of such exclusion on the validation
process remains unclear. Multiple imputation has proved
to be a useful approach for model estimation (e.g., [21]),
and could also be used for the validation stage. However,
the benefit of such imputation to estimate model perfor-
mance is uncertain. To reproduce the conditions of clin-
ical practice, we keep in our validation only the patients
with complete information. The subjects with missing
data were more likely to be 55 years and older, and to have
more nodal involvement, for similar stage and tumour
size (data not shown). As the predictions that take into
account relapse information were demonstrated to be
more appropriate in predicting high risk of death, it is pos-
sible that the performances of the prediction accounting
for the relapses were underestimated. In the end, the sur-
vival results of the analysed patients were in accordance
with the results of the EUROCARE-4 study [22]. In this
study, the age-adjusted 5-year survival was 81% for French
patients diagnosed between 1990 and 1994, and 78% and
83% for the patients diagnosed between 1995 and 1999 in
England and Netherlands, respectively.
Conclusion
The present work shows how recurrent events occurring
in breast cancer patients may be used to obtain accu-
rate prediction of death. The resulting calibration and
error of prediction show that the estimated prognostic
model is useful to predict the risk of death, in particu-
lar when enough variability in the number of recurrences
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Figure 5 Results of the prediction on the patients fromWest Midlands. A. Relative prediction error at the prediction time t = 5 years and a
prediction horizon from 5.5 to 15 years. B,C,D. Calibration plots for the three predictions. The upper part is for patients without relapse before 5
years; the lower part is for patients with at least one relapse observed before 5 years.
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is observed. Good calibration was obtained, especially
considering that the validation samples differed from the
development sample with respect to inclusion criteria for
the patients and period, country and therefore, health care
system. Using different incidence years is of great inter-
est, since the care (especially treatment and screening) of
breast cancer patients evolved during the 1990s, affecting
survival. It seems that finally, despite these differences, the
effect of covariates and relapses remained similar and was
still of interest. Therefore, the joint model for recurrent
event and a terminal event gives some accurate predic-
tions, and the specific studied model in breast cancer can
be used in different populations.
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